Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Core Insights - Incannex Healthcare Inc. has appointed Dr. Douglas B. Kirsch to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, enhancing the board's expertise at a crucial time for the program [1][2][4] Company Overview - Incannex is a clinical-stage biopharmaceutical company focused on developing combination drug therapies for significant health conditions, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [8] - The company's lead product, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide, designed to target the underlying mechanisms of obstructive sleep apnea [8] Product Development - IHL-42X is currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally, with topline Phase 2 data expected in July 2025 [5][6] - The therapy targets two physiological pathways associated with obstructive sleep apnea: intermittent hypoxia and hypercapnia, offering a differentiated approach that may benefit a broader range of patients [7] Clinical Expertise - Dr. Kirsch brings extensive experience in sleep medicine, having served as President of the American Academy of Sleep Medicine and currently overseeing clinical sleep medicine services at Atrium Health [2][3] - His addition to the advisory board is expected to be instrumental in advancing IHL-42X through late-stage development [2][4] Market Potential - Obstructive sleep apnea affects approximately 1 billion people globally and around 30 million in the United States, with a significant portion of cases remaining underdiagnosed and undertreated [7] - IHL-42X has the potential to address this critical gap in care, improving outcomes for millions suffering from this chronic condition [7]